Eric D Rabinovsky

Title: Eric D Rabinovsky: Innovator in Therapeutic Applications of IGF-I

Introduction

Eric D Rabinovsky is a notable inventor based in Houston, TX (US). He has made significant contributions to the field of therapeutic applications, particularly through his innovative work involving insulin-like growth factor I (IGF-I). His research focuses on enhancing angiogenesis and myogenesis, which are crucial for treating muscular and vascular complications associated with diabetes.

Latest Patents

Eric D Rabinovsky holds a patent for "Insulin-like growth factor (IGF-I) plasmid-mediated supplementation for therapeutic applications." This invention outlines a composition and method for stimulating angiogenesis, myogenesis, and upregulating angiogenic factors and angiopoietins. The patent describes a process that involves delivering a heterologous nucleic acid sequence encoding IGF-I into the cells of a subject, allowing for the expression of the encoded gene. The preferred delivery method is through in vivo electroporation, utilizing a vector system that includes a synthetic myogenic promoter.

Career Highlights

Eric is associated with Vgx Pharmaceuticals, Inc., where he continues to advance his research and development efforts. His work has the potential to significantly impact the treatment of diabetes-related complications, showcasing his commitment to improving patient outcomes through innovative therapies.

Collaborations

Eric D Rabinovsky collaborates with Ruxandra Draghia-Akli, contributing to the advancement of their shared research goals. Their partnership exemplifies the importance of teamwork in the field of medical innovation.

Conclusion

Eric D Rabinovsky is a pioneering inventor whose work in IGF-I applications holds promise for therapeutic advancements in diabetes treatment. His contributions to the field are noteworthy and reflect his dedication to innovation in healthcare.